| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fibroblasts | 9 | 2013 | 160 | 1.350 |
Why?
|
| Matrix Metalloproteinase 2 | 10 | 2014 | 40 | 1.230 |
Why?
|
| Myofibroblasts | 3 | 2012 | 23 | 0.840 |
Why?
|
| Platelet-Derived Growth Factor | 3 | 2009 | 26 | 0.810 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2009 | 77 | 0.780 |
Why?
|
| Actins | 7 | 2012 | 99 | 0.740 |
Why?
|
| Wound Healing | 7 | 2013 | 126 | 0.700 |
Why?
|
| Gelatinases | 7 | 1999 | 14 | 0.590 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 344 | 0.550 |
Why?
|
| Matrix Metalloproteinases | 3 | 2014 | 31 | 0.540 |
Why?
|
| Metalloendopeptidases | 6 | 1999 | 40 | 0.500 |
Why?
|
| Cell Movement | 3 | 2013 | 373 | 0.500 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2012 | 301 | 0.500 |
Why?
|
| Epithelium, Corneal | 1 | 2014 | 14 | 0.450 |
Why?
|
| Xenopus laevis | 1 | 2014 | 50 | 0.450 |
Why?
|
| Tight Junctions | 1 | 2014 | 29 | 0.440 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 76 | 0.430 |
Why?
|
| Silicone Elastomers | 1 | 2013 | 4 | 0.420 |
Why?
|
| Wounds and Injuries | 2 | 2012 | 191 | 0.420 |
Why?
|
| Focal Adhesions | 2 | 2012 | 15 | 0.420 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2013 | 8 | 0.410 |
Why?
|
| Genetic Carrier Screening | 1 | 2013 | 10 | 0.400 |
Why?
|
| Frameshift Mutation | 1 | 2013 | 14 | 0.400 |
Why?
|
| Granulation Tissue | 1 | 2012 | 7 | 0.400 |
Why?
|
| Wnt Proteins | 1 | 2013 | 34 | 0.400 |
Why?
|
| Pancreas | 1 | 2013 | 63 | 0.390 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2011 | 60 | 0.380 |
Why?
|
| Cells, Cultured | 8 | 2013 | 1009 | 0.340 |
Why?
|
| Rats | 10 | 2012 | 1587 | 0.330 |
Why?
|
| Animals | 20 | 2018 | 10583 | 0.310 |
Why?
|
| Up-Regulation | 1 | 2009 | 247 | 0.290 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 6 | 2014 | 9 | 0.290 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2007 | 15 | 0.270 |
Why?
|
| Vision, Ocular | 1 | 2007 | 27 | 0.270 |
Why?
|
| Base Sequence | 5 | 2013 | 588 | 0.270 |
Why?
|
| Signal Transduction | 3 | 2009 | 1455 | 0.240 |
Why?
|
| Rats, Inbred WKY | 4 | 2009 | 13 | 0.240 |
Why?
|
| Angiopoietin-2 | 1 | 2005 | 10 | 0.240 |
Why?
|
| Carrier Proteins | 1 | 2007 | 252 | 0.240 |
Why?
|
| Cell Line | 7 | 2012 | 698 | 0.240 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2005 | 39 | 0.230 |
Why?
|
| Gene Expression Regulation | 2 | 2005 | 633 | 0.220 |
Why?
|
| Cell Differentiation | 4 | 2012 | 419 | 0.210 |
Why?
|
| Calcium-Binding Proteins | 1 | 2003 | 62 | 0.190 |
Why?
|
| Lipoproteins | 1 | 2003 | 99 | 0.190 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 154 | 0.180 |
Why?
|
| Pepsin A | 2 | 1991 | 2 | 0.180 |
Why?
|
| DNA Primers | 2 | 2013 | 147 | 0.180 |
Why?
|
| Humans | 24 | 2013 | 28585 | 0.180 |
Why?
|
| Molecular Sequence Data | 5 | 2007 | 1056 | 0.170 |
Why?
|
| Eye Proteins | 1 | 2003 | 207 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 270 | 0.170 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2012 | 94 | 0.160 |
Why?
|
| Neoplasm Proteins | 2 | 1991 | 123 | 0.160 |
Why?
|
| Cytoskeleton | 2 | 1997 | 45 | 0.160 |
Why?
|
| Endocardium | 1 | 1999 | 16 | 0.160 |
Why?
|
| Serum Albumin, Bovine | 1 | 2018 | 22 | 0.150 |
Why?
|
| Nanotubes | 1 | 2018 | 15 | 0.150 |
Why?
|
| Melanoma, Experimental | 1 | 2018 | 31 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 68 | 0.140 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 5 | 2002 | 13 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2009 | 12 | 0.140 |
Why?
|
| Phenotype | 3 | 2012 | 682 | 0.140 |
Why?
|
| Mice | 7 | 2018 | 4735 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2012 | 523 | 0.140 |
Why?
|
| Serine Endopeptidases | 1 | 1997 | 19 | 0.140 |
Why?
|
| Embryonic Development | 1 | 1997 | 22 | 0.140 |
Why?
|
| Glycoproteins | 3 | 1997 | 123 | 0.140 |
Why?
|
| Gold | 1 | 2018 | 137 | 0.140 |
Why?
|
| RNA, Messenger | 4 | 2005 | 667 | 0.130 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 3 | 2009 | 11 | 0.130 |
Why?
|
| Glycation End Products, Advanced | 1 | 1996 | 17 | 0.130 |
Why?
|
| Enzyme Precursors | 3 | 1998 | 16 | 0.120 |
Why?
|
| Collagen | 1 | 1996 | 156 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2006 | 135 | 0.120 |
Why?
|
| Claudin-4 | 1 | 2014 | 2 | 0.110 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2014 | 3 | 0.110 |
Why?
|
| Occludin | 1 | 2014 | 12 | 0.110 |
Why?
|
| Enzyme Activation | 5 | 1998 | 267 | 0.110 |
Why?
|
| Genes, Reporter | 2 | 2006 | 87 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 113 | 0.110 |
Why?
|
| Muscle Contraction | 2 | 2009 | 171 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 1997 | 485 | 0.110 |
Why?
|
| Biological Assay | 1 | 2013 | 34 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 465 | 0.100 |
Why?
|
| Cell Culture Techniques | 2 | 2012 | 117 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 133 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 1602 | 0.090 |
Why?
|
| Cattle | 2 | 2018 | 388 | 0.090 |
Why?
|
| Protein Multimerization | 1 | 2012 | 57 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2009 | 415 | 0.090 |
Why?
|
| RNA Interference | 1 | 2012 | 137 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 134 | 0.090 |
Why?
|
| Breast Neoplasms | 3 | 2006 | 472 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2012 | 515 | 0.090 |
Why?
|
| Male | 5 | 2013 | 13772 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2013 | 732 | 0.090 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2010 | 3 | 0.080 |
Why?
|
| Activin Receptors, Type I | 1 | 2010 | 5 | 0.080 |
Why?
|
| Toxoplasmosis | 1 | 2010 | 11 | 0.080 |
Why?
|
| Toxoplasma | 1 | 2010 | 33 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 59 | 0.080 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2009 | 9 | 0.080 |
Why?
|
| Genes, fos | 1 | 2009 | 13 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2018 | 160 | 0.080 |
Why?
|
| Models, Biological | 1 | 2012 | 468 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 340 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2009 | 200 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 4 | 2003 | 314 | 0.070 |
Why?
|
| Estrogen Antagonists | 2 | 1998 | 16 | 0.070 |
Why?
|
| 5' Flanking Region | 1 | 2007 | 5 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 233 | 0.070 |
Why?
|
| Exons | 1 | 2007 | 42 | 0.070 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2007 | 24 | 0.070 |
Why?
|
| Luciferases | 1 | 2007 | 54 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2003 | 54 | 0.070 |
Why?
|
| Culture Media, Serum-Free | 1 | 2006 | 12 | 0.060 |
Why?
|
| Swine | 1 | 2007 | 238 | 0.060 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2006 | 5 | 0.060 |
Why?
|
| Transfection | 2 | 2006 | 319 | 0.060 |
Why?
|
| Kinetics | 4 | 2001 | 551 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2005 | 44 | 0.060 |
Why?
|
| RNA Stability | 1 | 2005 | 28 | 0.060 |
Why?
|
| Low-Level Light Therapy | 1 | 2005 | 9 | 0.060 |
Why?
|
| Female | 6 | 2013 | 15472 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 404 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 155 | 0.060 |
Why?
|
| Gene Expression | 2 | 2003 | 417 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 24 | 0.050 |
Why?
|
| Laser Therapy | 1 | 2003 | 30 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2003 | 48 | 0.050 |
Why?
|
| Receptors, sigma | 1 | 2003 | 5 | 0.050 |
Why?
|
| Technology, Pharmaceutical | 1 | 2003 | 9 | 0.050 |
Why?
|
| Cocaine | 1 | 2003 | 22 | 0.050 |
Why?
|
| Hippocalcin | 1 | 2003 | 4 | 0.050 |
Why?
|
| Recoverin | 1 | 2003 | 4 | 0.050 |
Why?
|
| Aged | 1 | 2013 | 5525 | 0.050 |
Why?
|
| Biomarkers | 1 | 2006 | 770 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 1341 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2003 | 275 | 0.050 |
Why?
|
| Cicatrix | 1 | 2002 | 14 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2003 | 111 | 0.050 |
Why?
|
| Skin | 2 | 2002 | 151 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2003 | 137 | 0.050 |
Why?
|
| Fetus | 1 | 2002 | 79 | 0.050 |
Why?
|
| RNA | 1 | 2003 | 111 | 0.050 |
Why?
|
| Protein Binding | 3 | 1998 | 664 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2005 | 361 | 0.050 |
Why?
|
| Middle Aged | 1 | 2013 | 7310 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2005 | 817 | 0.040 |
Why?
|
| Molecular Weight | 2 | 1991 | 122 | 0.040 |
Why?
|
| Cytosol | 1 | 2001 | 49 | 0.040 |
Why?
|
| Glycosylation | 2 | 2001 | 70 | 0.040 |
Why?
|
| Adult | 1 | 2013 | 7922 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 1998 | 190 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 236 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2001 | 695 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2000 | 3 | 0.040 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2000 | 2 | 0.040 |
Why?
|
| Carbazoles | 1 | 2000 | 6 | 0.040 |
Why?
|
| Botulinum Toxins | 1 | 2000 | 10 | 0.040 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2000 | 39 | 0.040 |
Why?
|
| Rats, Inbred SHR | 1 | 1999 | 13 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2000 | 79 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 31 | 0.040 |
Why?
|
| Lysophospholipids | 1 | 2000 | 51 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2001 | 202 | 0.040 |
Why?
|
| Antigens, Bacterial | 1 | 2001 | 164 | 0.040 |
Why?
|
| Indoles | 1 | 2000 | 110 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 1999 | 138 | 0.040 |
Why?
|
| Infrared Rays | 1 | 2018 | 24 | 0.040 |
Why?
|
| Phototherapy | 1 | 2018 | 28 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 45 | 0.040 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1998 | 11 | 0.040 |
Why?
|
| Culture Techniques | 1 | 1997 | 12 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 101 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 302 | 0.030 |
Why?
|
| Bacterial Toxins | 1 | 2001 | 269 | 0.030 |
Why?
|
| Pregnancy | 2 | 2002 | 1219 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1997 | 112 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 208 | 0.030 |
Why?
|
| Substrate Specificity | 3 | 2003 | 151 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 416 | 0.030 |
Why?
|
| Glucose-6-Phosphate | 1 | 1996 | 4 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 1996 | 42 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 448 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 1996 | 117 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2000 | 638 | 0.030 |
Why?
|
| Exudates and Transudates | 1 | 1995 | 11 | 0.030 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 1995 | 14 | 0.030 |
Why?
|
| Glucose | 1 | 1996 | 208 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 1996 | 215 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2006 | 332 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1995 | 273 | 0.030 |
Why?
|
| Hydrolysis | 2 | 2003 | 60 | 0.020 |
Why?
|
| Ataxia Telangiectasia | 1 | 1991 | 1 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1991 | 62 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 42 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1991 | 131 | 0.020 |
Why?
|
| Hydroxylation | 1 | 2010 | 9 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2010 | 6 | 0.020 |
Why?
|
| Binding Sites | 1 | 1991 | 354 | 0.020 |
Why?
|
| Protein Stability | 1 | 2010 | 43 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 80 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 208 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2002 | 554 | 0.020 |
Why?
|
| Oxygen | 1 | 2010 | 234 | 0.020 |
Why?
|
| Protease Inhibitors | 2 | 2000 | 40 | 0.020 |
Why?
|
| Collagenases | 2 | 1998 | 5 | 0.020 |
Why?
|
| Tamoxifen | 2 | 1998 | 33 | 0.020 |
Why?
|
| Estradiol | 2 | 1998 | 175 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 60 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 90 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 36 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 74 | 0.010 |
Why?
|
| Rats, Inbred WF | 1 | 2003 | 11 | 0.010 |
Why?
|
| Freeze Drying | 1 | 2003 | 10 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2003 | 25 | 0.010 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2003 | 15 | 0.010 |
Why?
|
| Colorimetry | 1 | 2003 | 15 | 0.010 |
Why?
|
| Carcinogens | 1 | 2003 | 39 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 22 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2003 | 164 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 278 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 104 | 0.010 |
Why?
|
| Motor Activity | 1 | 2003 | 148 | 0.010 |
Why?
|
| Gestational Age | 1 | 2002 | 146 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 328 | 0.010 |
Why?
|
| GTP Phosphohydrolases | 1 | 2001 | 19 | 0.010 |
Why?
|
| CHO Cells | 1 | 2001 | 96 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 131 | 0.010 |
Why?
|
| Ionomycin | 1 | 2000 | 4 | 0.010 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2000 | 4 | 0.010 |
Why?
|
| Myosin-Light-Chain Phosphatase | 1 | 2000 | 4 | 0.010 |
Why?
|
| Alkaloids | 1 | 2000 | 16 | 0.010 |
Why?
|
| Calcimycin | 1 | 2000 | 12 | 0.010 |
Why?
|
| Skin Physiological Phenomena | 1 | 2000 | 8 | 0.010 |
Why?
|
| Azepines | 1 | 2000 | 2 | 0.010 |
Why?
|
| ADP Ribose Transferases | 1 | 2000 | 4 | 0.010 |
Why?
|
| Naphthalenes | 1 | 2000 | 17 | 0.010 |
Why?
|
| rho-Associated Kinases | 1 | 2000 | 12 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2000 | 90 | 0.010 |
Why?
|
| Mutation | 1 | 2003 | 864 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 251 | 0.010 |
Why?
|
| Calcium | 1 | 2000 | 243 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 611 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1998 | 31 | 0.010 |
Why?
|
| Gelatin | 1 | 1998 | 11 | 0.010 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 1998 | 13 | 0.010 |
Why?
|
| Fibronectins | 1 | 1998 | 28 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2000 | 285 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 1997 | 43 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 169 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1997 | 681 | 0.010 |
Why?
|